Incidence of second cancers in patients treated for Hodgkin's disease.
about
Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer riskTherapy-related myeloid neoplasms - what have we learned so far?Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Radiation-induced skin cancer in humans.Second lethal events associated with treatment for Hodgkin's disease: a review of 2980 patients treated in a single Mexican institute.Second malignancies in Hodgkin's disease: A review of the literature and report of a case with a secondary Lennert's lymphomaSecond malignancies after treatment for Hodgkin's disease.Effect of organ size and position on out-of-field dose distributions during radiation therapy.Second cancers after radiotherapy: any evidence for radiation-induced genomic instability?Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden HospitalSubsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trialsSecond primary malignancies after treatment for malignant lymphoma.Should cancer survivors fear radiation-induced sarcomas?Cancer risk in systemic lupus: an updated international multi-centre cohort study.Is age an independent risk factor for chemically induced acute myelogenous leukemia in children?Gingival enlargement as an early diagnostic indicator in therapy-related acute myeloid leukemia: A rare case report and review of literatureAccelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.Therapy-related myelodysplasia and acute myeloid leukemiaRecent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women.XVI. Early stage Hodgkin lymphoma.Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.Second primary tumors in patients with cutaneous malignant melanoma.Second primary neoplasms in thyroid cancer patients.The case for adjuvant radiation therapy in advanced Hodgkin's disease.Second hematologic malignancies after ABVD: Two case reports and a retrospective study of 183 Hodgkin lymphoma patients.Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.Risk of second cancer after lymphohematopoietic neoplasm.
P2860
Q24245375-2528ACCB-50B2-4113-8F77-B8B89400D05CQ28071318-40D1180C-30CD-4E91-B13F-EAF4CB7E60C2Q33346685-2803AA0C-3749-46C7-AD9A-FE729988B071Q33945737-AE3707AE-A20C-4CE9-8E33-E721C294FA48Q34244422-75285002-84E0-45ED-AF2C-249278C8CBFDQ34412940-F052D5AB-5186-452D-8F3D-14CB83B94687Q34575623-DA65B85F-6681-4A35-B86B-977E89291529Q35153244-F2BDCC96-439B-45C2-9E81-25FD5506AFF9Q35559129-848F81A7-4A16-4B42-9BAB-060A6312D04FQ36419982-8646C50F-CE6D-4E3A-85DD-8AAE3198905BQ36491663-ACFCD64C-578B-4EB4-8A3A-376B65518A28Q36589635-D37D13AF-8FDB-49AE-9041-774876D5D4F1Q36615187-98D311F8-B520-434C-98D8-534D7DDA92A8Q36639305-5B93E6C0-8D3F-46CC-A2B4-543A9903539DQ36823763-EFF96CEE-DEE5-4B05-BAF6-BB144E9AF2A9Q36905628-30FC7AB2-51E9-458F-9BAB-2A36696E6612Q37020294-172A1A3F-849A-4078-B08D-7BD864F49C02Q37103073-3A68DB0E-7D53-44E2-BE93-F8BCCD9D6E95Q37402657-0C7679E4-FF70-452B-9AC9-446E4E3F1700Q38285627-B2021880-29FF-4A65-8722-612E133C25B1Q38446917-4646051D-DE23-40A7-880A-1CB5DF1D0CF2Q38461685-6D9153FC-35E4-4FBE-AA80-45B08DFEF560Q38524023-DAA173B4-573C-46DA-8AF8-89D6E73E705EQ40044179-1347D76A-7E87-42E5-8B6B-DBDF15ED72B1Q40345824-928D4AD0-6739-4640-A0F3-C7E1DB3AD6A5Q40789055-2EEF32C9-C0EB-4E5F-83FB-98AAF15DD4B5Q40977364-FD726911-9474-4066-BB7D-FC3AC2803886Q41020868-4A0B8E2D-68A3-4F57-8E3F-4A74DEAB46CFQ43258973-9000B3A9-99C0-49BD-9F1B-E43F77A7FF04Q43795697-1B818B3A-B454-4CBE-BDD5-E539AEBEB4F7Q44051866-08EAECEA-4FB8-42FE-BEA7-F57166B2B43BQ49932419-8E733C4C-55A4-48EF-B991-CB619417E013Q51539401-EA05C0A2-0A5D-4BA9-9F6E-1D339544EF41
P2860
Incidence of second cancers in patients treated for Hodgkin's disease.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Incidence of second cancers in patients treated for Hodgkin's disease.
@en
type
label
Incidence of second cancers in patients treated for Hodgkin's disease.
@en
prefLabel
Incidence of second cancers in patients treated for Hodgkin's disease.
@en
P2093
P356
P1476
Incidence of second cancers in patients treated for Hodgkin's disease.
@en
P2093
Bernstein L
Hutchison GB
P304
P356
10.1093/JNCI/87.10.732
P407
P577
1995-05-01T00:00:00Z